Orismilast, a PDE4B/D inhibitor, in moderate-to-severe atopic dermatitis: Efficacy and safety from a multicenter, randomized, placebo-controlled, phase 2b dose-ranging study (ADESOS).

Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease, characterized by eczematous skin lesions and pruritus. There is an unmet need for effective first-line systemic therapies with good safety profiles, particularly oral medications. Orismilast is a novel first-in-class oral phosphodiesterase-4 (PDE4) B/D inhibitor under investigation for the treatment of moderate-to-severe AD.

Morphological changes to peripheral joints supporting thumb trapezial metacarpal osteoarthritis.

The present study aims to determine if morphological differences of the scaphoid, trapezoid, and second metacarpal are associated with thumb osteoarthritis by comparing three-dimensional bone models of healthy controls and osteoarthritis patients. Fifty-eight patients with moderate to severe thumb osteoarthritis (modified Eaton ≥ II) and 35 healthy controls from a larger completed investigation were examined. To quantify morphological variations, a statistical shape model was created that classified binary with respect to the Eaton grading system: non-osteoarthritis or moderate/severe osteoarthritis (II-IV).

Patients with DCIS Seen at a Specialized High-Risk Breast Clinic Run by Surgical Advanced Practice Providers Have High Rates of Preventive Medication Uptake.

Background: Preventative medication (PM) uptake is low among patients at an elevated risk of breast cancer, largely due to fears of intolerance. This study aimed to investigate whether a new, surgical advanced practice provider (APP)-run clinic was effectively prescribing PM. We hypothesized equivalent rates of PM uptake compared to consultation with medical oncologists (MD).